Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.
FDA pregnancy medication categories : Pre 2015.
Mohamad Ali Salloum, PharmD • March 28, 2022
Share
Being pregnant brings to women so many questions. The questions can range from stuff related to how their bodies are affected, what should they eat, how much exercise should be done...etc.
All the questions are important to answer and make it clearer for the pregnant woman to prevent unnecessary bad things from happening. However, one of the most important questions to be asked is “What are the medications that can be administered during pregnancy and what are the medications to be avoided?”
In 1979, the FDA published a classification for the medications to organize them in a clearer way. The classification is called “FDA pregnancy categories” and there are 5 of them: A, B, C, D, and X.
Fast forward to 2015, and after receiving many comments that this categorization leaves the patients and the health care providers confused and may misinterpret the meaning of the letters, the FDA replaced it with new narrative information which will remove the confusion away. Hopefully :D
The new narrative description of medication safety is called the Pregnancy and Lactation Labeling Rule (PLLR).
So, the FDA requested that prescription drugs and biologic products submitted after June 30, 2015, will use the new format immediately. (1)
To understand more about why this update happened, let us first explore the previous categorization used. In this article we will talk about the FDA pregnancy risk categories used prior to 2015.
You can go to this article for more details about the 2015 update.
Category A (2)
Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).
Example drugs or substances:
Levothyroxine, Folic Acid, Thiamine, Pyridoxine, Doxylamine.
Category B (2)
Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
Example drugs:
Metformin, Hydrochlorothiazide, Cyclobenzaprine, Amoxicillin.
Category C (2)
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Example drugs:
Gabapentin, Amlodipine, Trazodone.
Category D (2)
There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Example drugs:
Losartan, Carbamazepine, Phenytoin.
Category X (2)
Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.
Example drugs:
Atorvastatin, Simvastatin, Methotrexate, Finasteride, Triazolam, Isotretinoin.
As a summary:
| Category | Safe to Use? | Examples |
|---|---|---|
| A | Yes | Paracetamol, Levothyroxine, Folic Acid |
| B | Yes | Amoxicillin, Cephalosporins, Metformin |
| C | Do Risk/Benefit assessment | Gabapentin, Trazodone, Amlodipine |
| D | Do Risk/Benefit assessment | Carbamazepine, Phenytoin, Losartan |
| X | No | Atorvastatin, Simvastatin, Ribavirin, Methotrexate |
Since you are now familiar with the categories, I think you have an idea why the FDA updated the requirements and why it is causing some confusion about their meaning.
Let’s go and explore the 2015 update and how the FDA is now requesting the pharmaceuticals to write down a narrative assessment in the drug labelling information. Click Here.
List of Services
ABOUT THE AUTHOR
Mohamad-Ali Salloum, PharmD
Share
Recent articles:
Low Mood is NOT random!
Learn how CBT rewires thoughts, emotions, and behaviors—and test your knowledge with a quick quiz.
A clear, engaging walkthrough of fentanyl’s pharmacokinetics and pharmacodynamics—from administration to metabolism and excretion—designed for pharmacy and medical students, with visuals, summaries, and an interactive quiz.
Understand Aspirin easily with this blog post.
Learn about Buprenorphine, the strong gripper, but weak pusher 😅
References : American Chemical Society. Tramadol – Molecule of the Week Archive. December 16, 2014. [acs.org] DEA Diversion Control Division. Tramadol Drug & Chemical Evaluation Section Report. April 2025. [deadiversi....usdoj.gov] Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879‑923. [go.drugbank.com] Food and Drug Administration (FDA). ULTRAM® (tramadol hydrochloride) tablets label. 2004. [accessdata.fda.gov] Nickson C. Tramadol – CCC Pharmacology. Life in the Fast Lane ; 2024. [litfl.com] DrugBank Online. Tramadol: Uses, Interactions, Mechanism of Action. DB00193. [go.drugbank.com] Food and Drug Administration (FDA). Tramadol Hydrochloride Tablets (DailyMed). 2023. [dailymed.nlm.nih.gov] Dean L. Tramadol Therapy and CYP2D6 Genotype. Medical Genetics Summaries . 2015. [ncbi.nlm.nih.gov] Food and Drug Administration (FDA). Tramadol ER Capsules Label Information. 2010. [accessdata.fda.gov] EBM Consult. Mechanism for Tramadol‑Induced Serotonin Syndrome in Patients Taking SSRIs. 2017. Medsafe Pharmacovigilance. Serious Reactions with Tramadol: Seizures and Serotonin Syndrome. 2007. Hassamal S, Miotto K, Dale W, Danovitch I. Tramadol: Understanding the Risk of Serotonin Syndrome and Seizures. Am J Med. 2018;131(11):1382.e1–6. Medscape Reference. Ultram, ConZip (tramadol) dosing, indications, interactions. 2026.
A thoughtful reflection on Declutter Your Mind, exploring mental clutter, awareness, negative thinking patterns, mindfulness, and practical habits for mental clarity.
References: Qiang S, Wu J, Zheng D, et al. The effect of stress mindset on psychological pain: the chain mediating roles of cognitive reappraisal and self-identity. Front Psychol. 2025;16. 1 Bosshard M, Gomez P. Effectiveness of stress arousal reappraisal and stressisenhancing mindset interventions on task performance outcomes: a meta-analysis. Sci Rep. 2024. 2 Zhao S, Chen P, Jin L, et al. Unlocking Emotional Well-Being: Evaluation of a Stress Mindset Intervention With a Metacognitive Approach. Emotion. 2025;25(5):1169–1184. 4 Meyer HH, Stutts LA. The Effect of Mindset Interventions on Stress and Academic Motivation in College Students. Innov High Educ. 2024;49:783–798. 7 Crum AJ, Santoro E, Handley-Miner I, et al. Evaluation of the “Rethink Stress” Mindset Intervention: A Metacognitive Approach to Changing Mindsets. J Exp Psychol Gen. 2023. 3 Laferton JAC, Fischer S, Ebert DD, et al. The Effects of Stress Beliefs on Daily Affective Stress Responses. Ann Behav Med. 2020;54(4):258–267. 5 UCSF Stress Measurement Network. Beliefs about Stress . 2026. 6
References: Qiang S, Wu J, Zheng D, et al. The effect of stress mindset on psychological pain: the chain mediating roles of cognitive reappraisal and self-identity. Front Psychol. 2025;16. 1 Bosshard M, Gomez P. Effectiveness of stress arousal reappraisal and stressisenhancing mindset interventions on task performance outcomes: a meta-analysis. Sci Rep. 2024. 2 Zhao S, Chen P, Jin L, et al. Unlocking Emotional Well-Being: Evaluation of a Stress Mindset Intervention With a Metacognitive Approach. Emotion. 2025;25(5):1169–1184. 4 Meyer HH, Stutts LA. The Effect of Mindset Interventions on Stress and Academic Motivation in College Students. Innov High Educ. 2024;49:783–798. 7 Crum AJ, Santoro E, Handley-Miner I, et al. Evaluation of the “Rethink Stress” Mindset Intervention: A Metacognitive Approach to Changing Mindsets. J Exp Psychol Gen. 2023. 3 Laferton JAC, Fischer S, Ebert DD, et al. The Effects of Stress Beliefs on Daily Affective Stress Responses. Ann Behav Med. 2020;54(4):258–267. 5 UCSF Stress Measurement Network. Beliefs about Stress . 2026. 6
A clear, evidence‑based guide to Ramadan fasting, explaining its metabolic, mental, and cardiometabolic benefits, plus practical nutrition, hydration, sleep, and medication strategies for healthy adults and high‑risk patients.